Supriya Lifescience’s Ambernath facility receives WHO GMP certification

With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants

Relonchem receives marketing authorization for Moxonidine tablets

Shilpa Medicare receives initial authorization for Rivaroxaban Orodispersible films from EMA

Real-world data shows strong symptom relief and patient satisfaction with Teva’s Austedo XR

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States

ZyVet launches first generic treatment for canine urinary incontinence

Biocon inaugurates first US manufacturing facility in New Jersey

MHRA approves UK’s first new type of antibiotic for urinary tract infections

As with any medicine, the MHRA will keep the safety of gepotidacin under close review

Enanta files patent infringement suit against Pfizer

The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists